Company intelligence / Profile preview

Medigus

Ownership: Public · MDGS
Development stage: Commercial

Overview

Medigus developed and markets the MUSE system for minimally invasive treatment of GERD. The company also produces various endoscopes and micro cameras for medical and industrial use. It has diversified into digital commerce and electric vehicle technology through investments/subsidiaries.

Therapeutic areas: OtherGastroenterology
Modalities: DeviceImaging equipment
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

MUSE

Commercial

Indications: Gastroesophageal reflux disease

Partnerships

Polyrizon collaboration with NurExone Biologic Inc.

Financials

Market cap: $178.9M
Total revenue: $53.4M
Enterprise value: $176.1M

Beyond the preview

Go deeper on Medigus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medigus.

Explore the full profile